RE:Earnings chatRegardless of what the next 2 quarters earnings yield, shorty will dump into it and find inappropriate pieces. IMHO I see earnings being positive (excluding exceptional items) for every quarter moving forward. I know better than to give any EPS number, but I dont see the NHS drop in Rx value per prescription kicking in untill Q1 2017. Hence top line sales will be affected by NA Market Share erosion of in line products and GBP valuation. I will not be surprised to see EPS (excluding exceptional items) reduced vs last quarter by 30% untill new product revenues start appearing. This may change if we decide to extend an olive branch and voluntarily reduce prices as a sign of good faith during the public debate. The British policy makers are accountable to make changes and will work alongside industry to chisel out new pricing programs into 2H 2017. I see ongoing top line revenues from all sources, new and old drugs, will be constant averaged in the short/medium term over the next 18 months. Operating income will be dropped though. As the business model stabilizes into 2018/19, return to double digit growth should occur and SP will be 6-10x current prices, as the press gets bored with this topic and new acquisitions are made and prescription markets grow from chonic diseases.